Company news
BioCardia, Inc. news in 2023
BioCardia, Inc.'s news releases, calls and decks from 2023, newest first.
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
December 18, 2023
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
December 17, 2023
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
November 28, 2023
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
November 15, 2023
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
November 13, 2023
BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results
November 7, 2023
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
October 31, 2023
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
October 10, 2023
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
September 5, 2023
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
September 4, 2023
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
August 8, 2023
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
August 1, 2023
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
July 23, 2023
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
July 4, 2023
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
June 19, 2023
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
June 7, 2023
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
May 22, 2023
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
May 9, 2023
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
May 8, 2023
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
May 2, 2023
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
April 27, 2023
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
April 3, 2023
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
March 28, 2023
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
March 15, 2023
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
March 5, 2023
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
January 31, 2023
Calls in 2023
Decks in 2023
- Next Generation Cardiovascular Drug Development Summit (April 2023)
Conference · 24 slides · Apr 28, 2023